Literature DB >> 9246037

Hepatobiliary cystadenocarcinoma without ovarian stroma and normal CA 19-9 levels. Unusually prolonged evolution.

Y Horsmans1, A Laka, B E van Beers, C Descamps, J F Gigot, A P Geubel.   

Abstract

Hepatobiliary cystadenoma and cystadenocarcinoma are rare tumors of the liver. The differential diagnosis of cystadenoma includes other cystic neoplasms, nonneoplastic cysts, and even on some occasions parasitic liver involvement. It has been suggested that elevated serum level of the tumor marker CA 19-9 may be of value in distinguishing between cystadenoma with ovarian stroma and hydatid disease. We report the unique case of a male patient with a hepatobiliary cystadenocarcinoma without ovarian stroma of prolonged evolution characterized by a normal CA 19-9 serum level, low cyst fluid CA 19-9, and a very weak CA 19-9 expression on cyst epithelium.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9246037     DOI: 10.1023/a:1018842021677

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  7 in total

1.  Serum and cystic fluid CA 19-9 determinations as a diagnostic help in liver cysts of uncertain nature.

Authors:  Y Horsmans; A Laka; J F Gigot; A P Geubel
Journal:  Liver       Date:  1996-08

2.  Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures.

Authors:  S M Hsu; L Raine; H Fanger
Journal:  J Histochem Cytochem       Date:  1981-04       Impact factor: 2.479

Review 3.  Hepatobiliary cystadenoma with mesenchymal stroma.

Authors:  O E Akwari; A Tucker; H F Seigler; K M Itani
Journal:  Ann Surg       Date:  1990-01       Impact factor: 12.969

4.  Cystadenoma with mesenchymal stroma (CMS) in the liver and bile ducts. A clinicopathologic study of 17 cases, 4 with malignant change.

Authors:  D A Wheeler; H A Edmondson
Journal:  Cancer       Date:  1985-09-15       Impact factor: 6.860

5.  Elevated serum CA 19-9 levels in hepatobiliary cystadenoma with mesenchymal stroma. Two case reports with immunohistochemical confirmation.

Authors:  J A Thomas; M W Scriven; M C Puntis; B Jasani; G T Williams
Journal:  Cancer       Date:  1992-10-01       Impact factor: 6.860

6.  Mucin-histochemical and immunohistochemical profiles of epithelial cells of several types of hepatic cysts.

Authors:  T Terada; Y Nakanuma; T Ohta; T Nagakawa; Y Motoo; A Harada; N Hamato; T Inaba
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1991

7.  Hepatobiliary cystadenoma and cystadenocarcinoma. A light microscopic and immunohistochemical study of 70 patients.

Authors:  K Devaney; Z D Goodman; K G Ishak
Journal:  Am J Surg Pathol       Date:  1994-11       Impact factor: 6.394

  7 in total
  4 in total

1.  Utility of serum CA19-9 in diagnosis of cholangiocarcinoma: in comparison with CEA.

Authors:  Xing-Lei Qin; Zhuo-Ren Wang; Jing-Sen Shi; Min Lu; Lin Wang; Quan-Ru He
Journal:  World J Gastroenterol       Date:  2004-02-01       Impact factor: 5.742

2.  The surgical management of congenital liver cysts.

Authors:  J F Gigot; S Metairie; J Etienne; Y Horsmans; B E van Beers; C Sempoux; P Deprez; R Materne; A Geubel; D Glineur; P Gianello
Journal:  Surg Endosc       Date:  2001-03-13       Impact factor: 4.584

3.  Laparoscopic management of benign liver diseases: where are we?

Authors:  Jean-François Gigot; Catherine Hubert; Radu Banice; Michael L Kendrick
Journal:  HPB (Oxford)       Date:  2004       Impact factor: 3.647

4.  Hepatobiliary cystadenocarcinoma without mesenchymal stroma in a female patient: a case report.

Authors:  Yang-Hong Dai; Yee Hui Yeo; Yao-Feng Li; Chung-Bao Hsieh; Yu-Lueng Shih
Journal:  BMC Gastroenterol       Date:  2014-06-16       Impact factor: 3.067

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.